Prime Medicine Announces Pricing of Public Offering of Common Stock

Résumé détaillé

CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic…

CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an underwritten public offering of 35,714,286 shares of its common stock at a public offering price of $3.50 per share. Prime Medicine has also granted the underwriters a 30-day option to purchase up to an additional 5,357,142 shares of its common stock.

Jefferies, TD Cowen and Goldman Sachs & Co. LLC are acting as joint book-running managers for the offering. Oppenheimer & Co. and LifeSci Capital are acting as passive book-running managers for the offering.

The shares of common stock are being offered by Prime Medicine pursuant to a shelf registration statement on Form S-3ASR (File No. 333-291348) filed with the U.S. Securities and Exchange Commission (SEC) on November 7, 2025, as amended by that certain Post-Effective Amendment No. 1 to Form S-3 (No. 333-291348) and that certain Post-Effective Amendment No. 2 to Form S-3 (No. 333-291348), each filed with the SEC on March 3, 2026, and declared effective by the SEC on March 4, 2026. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement.

The final prospectus supplement relating to and describing the final terms of the offering will be filed with the SEC and, when available, may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com or Goldman Sachs & Co.

Début de l'article, extrait de Yahoo Finance. Pour lire la suite, ouvrez l'article chez le média.